An Open One-Step RT-qPCR for SARS-CoV-2 detection

Ariel Cerda[1,2†], Maira Rivera[1,3†], Grace Armijo[1,2**], Catalina Ibarra-Henriquez[1,2**], Javiera Reyes[1,3], Paula Blázquez-Sánchez[1,3], Javiera Avilés[1], Aníbal Arce[1], Aldo Seguel[1], Alexander J. Brown[4,5], Yesseny Vásquez[6], Marcelo Cortez-San Martín[7], Francisco A. Cubillos[1,7], Patricia García[8], Marcela Ferres[8], César A. Ramírez-Sarmiento[1,3*], Fernán Federici[1,2, 3*], Rodrigo A. Gutiérrez[1,2*].

1. ANID - Millennium Science Initiative Program - Millennium Institute for Integrative Biology (iBio)
2. FONDAP Center for Genome Regulation. Departamento de Genética Molecular y Microbiología, Pontificia Universidad Católica de Chile, Santiago, 8331150, Chile.
3. Institute for Biological and Medical Engineering, Schools of Engineering, Medicine and Biological Sciences, Pontificia Universidad Católica de Chile, Santiago, Chile.
4. Department of Biomedical Research, National Jewish Health, Denver, CO, USA
5. Department of Immunology & Microbiology, University of Colorado Anschutz Medical Campus, Aurora, CO, USA
6. Escuela de Ciencias Médicas. Facultad de Medicina. Universidad de Santiago de Chile. USACH, Santiago, Chile.
7. Departamento de Biología, Facultad de Química y Biología, Universidad de Santiago de Chile, USACH, Santiago, Chile.
8. Departamento de Laboratorios Clínicos. Escuela de Medicina. Facultad de Medicina. Pontificia Universidad Católica de Chile, Santiago, Chile.

† These authors equally contributed to this work.
* Corresponding authors to whom correspondence should be addressed:

*Cesar A. Ramirez-Sarmiento
Institute for Biological and Medical Engineering
Schools of Engineering, Medicine and Biological Sciences
Pontificia Universidad Católica de Chile
Av. Vicuña Mackenna 4860, Santiago, Chile
cesar.ramirez@uc.cl

*Fernan Federici
Dept. Molecular Genetics and Microbiology
School of Biological Sciences
Pontificia Universidad Católica de Chile
Av. Libertador Bernardo O`Higgins 340, Santiago, Chile
ffederici@bio.puc.cl

*Rodrigo A. Gutiérrez, PhD
Dept. Molecular Genetics and Microbiology
School of Biological Sciences
Pontificia Universidad Católica de Chile
Av. Libertador Bernardo O`Higgins 340, Santiago, Chile
Tel: +56 2 2686-2663; Fax: +56 2 2222-5515
rgutierrez@bio.puc.cl

Abstract

The COVID-19 pandemic has resulted in millions of deaths globally, and while several

diagnostic systems were proposed, real-time reverse transcription polymerase chain reaction

(RT-PCR) remains the gold standard. However, diagnostic reagents, including enzymes used

in RT-PCR, are subject to centralized production models and intellectual property restrictions,

which present a challenge for less developed countries. With the aim of generating a

standardized One-Step open RT-qPCR protocol to detect SARS-CoV-2 RNA in clinical

samples, we purified and tested recombinant enzymes and a non-proprietary buffer. The

protocol utilized M-MLV RT and Taq DNA pol enzymes to perform a Taqman probe-based

assay. Synthetic RNA samples were used to validate the One-Step RT-qPCR components,

and the kit showed comparable sensitivity to approved commercial kits. The One-Step RT-

qPCR was then tested on clinical samples and demonstrated similar performance to

commercial kits in terms of positive and negative calls. This study represents a proof of

concept for an open approach to developing diagnostic kits for viral infections and diseases,

which could provide a cost-effective and accessible solution for less developed countries.

Keywords SARS-CoV-2; One-Step RT-PCR; Open Source; Diagnostic system;

Recombinant enzymes.

Introduction

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the etiological agent of the coronavirus disease 2019 (COVID-19)[1], has infected more than 619 million individuals and killed over 6 and a half million people worldwide (weekly epidemiological update on COVID-19, 11 October 2022, World Health Organization[2]). However, the actual number of cases is likely higher, with recent estimates from the WHO suggesting that excess mortality caused by the pandemic may be as high as 14.9 million [3]. Oversaturation of local health systems and persistent scarcity of testing supplies and personal protective equipment (PPE), particularly in developing countries, have hindered early diagnosis and impeded the control and monitoring of virus transmission [4-7]. This has resulted in significant underestimation of the number of infected individuals, posing challenges for the efficient management of health resources [8,9].

To confirm suspected cases of COVID-19, various diagnostic systems have been proposed, including molecular, serological, viral culture, and chest computed tomography imaging methods [10-14]. While each of these methods provides valuable information to guide public healthcare decision-making, real-time reverse transcription polymerase chain reaction (RT-PCR) remains the gold standard approach for SARS-CoV-2 diagnosis due to its high sensitivity, specificity, and rapid detection [15-19]. One-Step RT-qPCR is the most commonly used technique for SARS-CoV-2 diagnosis and is recommended by health authorities worldwide [20,21]. The CDC-approved One-Step RT-qPCR Diagnostic Panel employs oligonucleotides that have been tested to avoid cross-reactivity with other human coronaviruses or common respiratory pathogens. Additionally, the performance of these oligonucleotides is continually monitored to ensure their efficacy against new variants of concern (VOC), such as the Delta and Omicron variants [21-25].

The unprecedented amount of testing needed during the COVID-19 pandemic, particularly

during the first few months, caused supply-chain shortages that prevented researchers and

clinicians worldwide from performing testing by RT-qPCR. As a result, numerous initiatives

were undertaken to overcome this problem [26-29]. Most approaches focused on the two

steps that were most affected by the availability of diagnostic testing supplies: viral RNA

extraction from patient samples and amplification/detection systems. Simplifying RNA

extraction methods addressed the shortage of RNA extraction kits by pooling nasopharyngeal

samples [30-34] or using alternative homemade simple RNA extraction methods [35-38].

Some reports described direct testing protocols without RNA extraction or replacing the

extraction with simple chemical or temperature treatment of the samples [27,39-43].

Unfortunately, finding alternatives for the reagents used in the detection and amplification of

viral RNA is difficult, mainly because they have a higher cost, require more specialized

infrastructure, and the enzymes used in diagnostic protocols are usually subject to centralized

production models and intellectual property restrictions [44,45]. This issue has become

particularly relevant for low-middle income countries (LMIC), particularly in the Southern

Hemisphere, where reagents are imported, and local means to produce them are scarce

[46,47]. Thus, strategies are required to ensure the access, production, and transfer of these

components between researchers to facilitate the tracing and testing of emerging pathogens

in LMICs.

Open-source communities have been promoting global collaboration, more accessible

solutions and distributed responses since the beginning of the COVID-19 pandemic. They

have offered low-cost alternatives to commercial reagents, free and open-source scientific

and medical Hardware (FOSH) and PPE [36,48-51]. In the context of diagnostic supplies, the

goal is to replace expensive commercial kits with master mixes made up of easy-to-obtain

reagents and homemade enzymes that can be produced and implemented locally and at low

cost. Currently, few open protocols or resources are available that grant autonomy or cost

reduction to LMIC in COVID-19 diagnostic methods [36,52-55]. For instance, Graham et al.

(2021) generated straightforward protocols for RNA extraction and RT-qPCR, which provides

an open-source master mix for detecting SARS-CoV-2 with results comparable to commercial

kits in nasopharyngeal swab samples and a detection limit of ~50 RNA copies. Furthermore,

a "blueprint" to replicate RT-qPCR kits in academic laboratories has been proposed to

overcome diagnostic supply shortages. This can be modified and adapted to resource-limited

settings [54]. Finally, the use of enzymes with reverse transcriptase (RT) and DNA

polymerase activity (DNA pol) for one-enzyme RT-qPCR approaches has also been explored.

For example, there is a dye-based RT-qPCR assay that employs the thermostable reverse

transcriptase/DNA polymerase (RTX) [52,54,56] and a probe-based RT-qPCR assay that

exploits the intrinsic RT activity of Taq DNA polymerase [57]. Despite these efforts, more RT-

qPCR approaches to detect SARS-CoV-2 using non-commercial, readily procurable

reagents, and easily shareable off-patent enzymes are still needed.

With the aim of contributing to these efforts, we present a standardized One-Step open RT-

qPCR protocol that is based on the local production of recombinant enzymes available in the

public domain, along with the generation of a non-proprietary buffer. The protocol outlined

here allows for performing a Taqman probe-based assay using the Moloney Murine Leukemia

Virus reverse transcriptase (M-MLV RT) [55] and Taq DNA polymerase (Taq DNA pol)

enzymes [36]. The open RT-qPCR master mix described herein was evaluated on synthetic

RNA and synthetic samples and did not show significant differences compared to the

commercial RT-qPCR kit. Furthermore, detailed protocols for the purification of the RT and

DNA pol enzymes, as well as the preparation of the homemade reaction buffer, are provided.

This work, along with the genetic resources for the production and subsequent purification of

the enzymes used in this study, is part of the Reagent Collaboration Network or ReClone

(https://reclone.org), which ensures open and expeditious access to resources through an

open material transfer agreement (openMTA)[58].

Results

Enzyme Purification and Standardization of One-Step RT-PCR

To develop an open-source master mix for a probe-based One-Step RT-qPCR, the following

recombinant enzymes were expressed and purified: (i) a highly processive and thermostable

M-MLV RT (D200N, L603W, T330P, L139P, and E607K point mutations) was used for cDNA

generation[59]. (ii) Taq DNA pol was used for DNA amplification[36]. (iii) To assess the

performance of a dye-based RT-qPCR not dependent on probes, Pfu-Sso7d polymerase was

also produced and purified[60]. Briefly, M-MLV RT, Taq DNA pol and Pfu-Sso7d were

obtained by IPTG-induced protein overexpression in *Escherichia coli* cells and purified using

a two-step process of nickel-nitrilotriacetic acid (Ni-NTA) immobilized metal affinity

chromatography (IMAC) followed by heparin affinity chromatography (Materials and Methods

section). The protein-containing fractions were pooled and analyzed by SDS-

PAGE **(Supplemental Figure 1).**

The activity of the purified enzymes was tested using two experimental approaches. First,

Pfu-Sso7d and M-MLV RT were used in a two-step RT-PCR assay with a known RNA sample.

Different commercial reaction buffers and commonly used reducing agents, namely beta-

mercaptoethanol (BME) and dithiothreitol (DTT), were tested in this experiment. The rationale

behind testing two different reducing agents is the significant difference in price and stability

in solution between these two chemicals[61]. A DNA band of the expected size was obtained

regardless of the buffer and reducing agent used. However, the best results were obtained

when DTT was added as the reducing agent **(Supplemental Figure 2A)**. Subsequently, a

homemade 5X reaction buffer (HM-Buffer, described in Material & Methods) was tested for

One-Step RT-PCR using M-MLV RT for cDNA synthesis and either Taq DNA pol

(**Supplemental Figure 2B**) or Pfu-Sso7d (**Supplemental Figure 2C**) for DNA amplification.

A band of the expected size was obtained in both One-Step RT-PCR approaches using either

0.5 or 1 µg of total DNAse-treated RNA as a template (**Supplemental Figure 2B, C**).

One-Step RT-qPCR validation using synthetic RNA from SARS-CoV-2

Once the components of the One-Step RT-qPCR were tested and validated, the homemade

master mix was evaluated using synthetic SARS-CoV-2 RNA samples. First, the SARS-CoV-

2 nucleocapsid (N) gene was *in vitro* transcribed and treated with DNAse I to remove template

DNA. Subsequently, the synthetic RNA of the N gene was purified, resulting in 50 µL of RNA

at a concentration of 1000 ng/µL, which was then serially diluted to obtain different target

concentrations (details in Materials and Methods). Synthetic RNA of N gene from MERS-CoV

and SARS-CoV-1 were also synthesized to use as negative controls. Then, a probe-based

assay relying on the reverse transcriptase activity of M-MLV and the DNA polymerase activity

of Taq DNA pol was performed using the *in vitro* transcribed viral RNA template. CDC-

recommended primers and double-quenched probes (Center for Disease Control and

Prevention, [20]) were used to amplify fragments of 72 bp (N1 pair) and 67 bp (N2 pair) within

the SARS-CoV-2 N gene (details in Material & Methods section). The 5' exonuclease activity

necessary for degrading the probes in this assay is provided by the Taq DNA pol enzyme.

The reaction mix was prepared as indicated in **Table 1**, and the thermal cycling protocol

utilized is described in **Table 2**. Representative results of the in-house probe-based One-Step

RT-qPCR assay using different dilutions of synthetic RNA are shown in **Figure 1**.

Table 1. One-Step RT-qPCR reaction mix using M-MLV RT and Taq DNA pol.

One-Step RT-qPCR (M-MLV/Taq)		
	Volume (µL)	Final Concentration
RNA sample	5	-
Combined Primer/Probe Mix (6,7 µM primers / 1.7 µM probe)	1.5	500 nM (forward and reverse primers) 125 nM (probe)
10 mM dNTPs	0.8	400 nM
5X Homemade Buffer	4	1X
100 mM DTT	2	10 mM
Taq DNA Pol (0.4 mg/mL)	1	20 ng/µL
M-MLV RT (0.02 mg/mL)	1	1 ng/µL
Nuclease-Free Water	4.7	-
Total Reaction Volume	20	

194
195

Table 2. One-Step RT-qPCR cycling conditions.

Step	Temperature (°C)	Duration
1	50	10 min
2	95	2 min
Repeat steps 3 and 4 by 40 cycles		
3	95	3 s
4*	55	30 s

*In this step fluorescence signal acquisition occurs (FAM)

As shown in **Figure 1**, the probe-based One-Step RT-qPCR assay enabled the detection of

synthetic RNA copies of the SARS-CoV-2 N gen using both sets of primers **(Figure 1A and**

B), detecting up to 10 copies of the N gene per reaction. Considering the total reaction volume

of 20 µL **(Table 1)**, this number of copies is equivalent to approximately 500 copies of RNA

per mL, which is similar to the limit of detection (LOD) of some approved kits for SARS-CoV-

2 detection[62], as well as other published open RT-qPCR methods[36].

Figure 1: CDC SARS-CoV-2 N1 and N2 probe-based One-Step RT-qPCR assays performed with synthetic RNA using homebrew M-MLV RT and Taq DNA pol. (A-B) Representative amplification curves using N1 and N2 CDC-approved double-quenched probes. Each curve represents a specific dilution of SARS-CoV-2 synthetic N RNA used as template: 1.4 x 10^7 copies approximately (red line), 1.4 x 10^6 (yellow line), 1.4 x 10^5 (green line), 1.4 x 10^4 (light blue line), 1.4 x 10^3 (blue line), 1.4 x 10^2 (purple line), 1.4 x 10^1 (light brown line) and no template control (NTC, gray line). Amplification curves for synthetic N RNA from MERS-CoV (bla ck dashed line) and SARS-CoV-1 (orange dashed line) are also indicated. Characteristic Cq values are indicated on the upper left side of each panel. N.d.: non-detected (no Cq reported).

Furthermore, no signal was obtained in the No-Template Controls (NTCs) or with synthetic RNAs from MERS-CoV and SARS-CoV-1. These results demonstrate that the locally produced enzymes and homemade master mix used in this One-Step RT-qPCR setup based on Taqman probes allow for sensitive detection of synthetic RNA from SARS-CoV-2, providing a wide dynamic range (from 10 to 10^7 RNA copies per reaction).

Alternatively, a dye-based RT-qPCR using homemade M-MLV RT and Pfu-Sso7d enzymes was also assessed as a probe-independent option, avoiding the use of expensive sequence-specific fluorescently-labeled probes. This detection system, which only requires PCR primers and an intercalating dye, offers an attractive and cost-effective alternative to Taqman probes. In this assay, the EvaGreen DNA-binding agent and the same set of primers for N1

and N2 were used (Material & Methods section). The reaction buffer used for each primer set

is shown in **Supplemental Table 1**, and RT-qPCR cycling conditions are described in

Supplemental Table 2. Representative results using synthetic RNA templates are shown in

Supplemental Figure 3. Additionally, a melting curve analysis was performed to confirm the

amplification of a specific product, as the fluorescent signal generated by intercalating dye

molecules (e.g., EvaGreen and SYBR Green) is not sequence-specific.

The dye-based One-Step RT-qPCR assay detected approximately 100 copies of synthetic

SARS-CoV-2 RNA per reaction (equivalent to 5,000 copies of RNA per mL), which is at least

one order of magnitude lower than the LOD of commercial kits[62]. However, there was

nonspecific amplification observed in NTC and low-concentration RNA samples, despite the

efforts made to optimize the components of the RT-PCR master mix. Melting curve analysis

of N1 and N2 shown in **Supplemental Figure 3** suggests that the results obtained could be

due to cross-contamination with synthetic RNA in the N1 primer set and primer dimers in the

N2 primer set. Taken together, these findings indicate that a probe-based One-Step RT-qPCR

approach using homemade M-MLV RT and Taq DNA pol is more suitable for SARS-CoV-2

synthetic RNA detection and represents a viable alternative for further testing in the diagnosis

of clinical samples.

Validation of a Taqman probe-based One-Step RT-qPCR in clinical samples

After confirming the accuracy and sensitivity of the probe-based One-Step RT-qPCR master

mix for detecting synthetic SARS-CoV-2 RNA, validation was performed using clinical

samples. CDC-recommended primers and probes that amplify the N1 and N2 targets of the

SARS-CoV-2 nucleocapsid (N) protein were used, as previously described. Additionally, the

human RNAse P gene target was also amplified as an endogenous internal control.

Two kits were used to evaluate 40 clinical nasopharyngeal samples: a commercial kit

(TaqPath™ 1-Step RT-qPCR Master Mix) and a homemade Taqman probe-based One-Step

reaction mix using locally produced M-MLV RT and Taq DNA pol. These samples had

previously been analyzed and classified in a clinical laboratory according to RT-qPCR

guidelines recommended by CDC [20] (20 positives and 20 negative samples). The results

obtained with the probe-based reaction mix were comparable to those of the commercial kit,

as evidenced by the Cq values obtained for both kits in each of the primer/probe sets (N1,

N2, and RNAse P) presented in **Table 3**. None of the previously reported negative samples

exhibited signal or amplification, indicating that this probe-based assay has 100% specificity

or "true negative rate" (20/20 successfully assigned negative samples).

All samples that had previously been reported as positive were found to be positive in the

current assay, except for one sample that could not be accurately identified as positive using

either the commercial or the homemade kit. This indicates that the sensitivity of the probe-

based test is 95% (19/20 positive samples were correctly identified). Additionally, all samples

showed amplification for RNAse P primers/probe mix, whether using the commercial kit

(mean Cq value of 27.82) or the homemade probe-based kit (mean Cq value of 27.99). Strong

correlation (r^2 = 0.9803 and r^2 = 0.9754, respectively, both with a *P*-value<0.0001) was

observed between the Cq values of the positive samples in both kits, regardless of whether

the N1 or N2 primer/probe set was employed **(Figure 2)**. **Figure 2** also shows that all the

negative samples are clustered in the section of samples where neither kit was able to detect

SARS-CoV-2 N RNA (N.d: non-detected Cq value). This zone also contains sample 20 (upper

right corner of **Figures 2A** and **2B**), the positive sample that was mislabeled as negative by

both kits.

Table 3. Comparative Cq data between a commercial RT-qPCR kit and an Open RT-qPCR method based on homebrew M-MLV RT and Taq DNA pol.

# Sample	ID	Commercial Kit				Open RT-qPCR (M-MLV/Taq)			
		N1	N2	RNAse P	Report	N1	N2	RNAse P	Report
1	*1215-023* (+)	13.28	14.01	26.42	Positive	14.53	14.97	26.08	Positive
2	*1229-055* (+)	14.40	14.08	28.31	Positive	15.97	16.47	28.09	Positive
3	*1228-001* (+)	18.35	19.51	27.17	Positive	19.43	20.22	27.64	Positive
4	*1228-048* (+)	18.46	17.95	25.41	Positive	19.36	18.26	26.31	Positive
5	*1230-140* (+)	18.78	18.97	25.66	Positive	19.68	19.1	29.15	Positive
6	*1228-047* (+)	19.57	19.54	30.80	Positive	17.67	18.29	28.00	Positive
7	*1228-066* (+)	19.98	19.76	25.05	Positive	20.49	19.97	25.35	Positive
8	*1230-024* (+)	20.27	20.62	28.46	Positive	20.72	21.42	27.13	Positive
9	*1229-034* (+)	20.41	20.91	31.95	Positive	20.72	20.76	31.40	Positive
10	*1228-035* (+)	21.05	20.20	31.81	Positive	21.88	22.64	33.91	Positive
11	*1228-096* (+)	23.55	23.29	25.71	Positive	25.75	23.52	25.70	Positive
12	*1230-096* (+)	23.60	23.12	27.37	Positive	23.58	23.72	26.47	Positive
13	*1230-142* (+)	24.20	24.84	31.77	Positive	25.38	25.76	30.61	Positive
14	*1229-054* (+)	24.24	24.35	27.38	Positive	24.88	26.46	27.68	Positive
15	*1228-040* (+)	25.73	25.39	27.73	Positive	26.82	25.83	27.95	Positive
16	*1230-101* (+)	26.10	25.91	30.24	Positive	27.94	26.28	33.47	Positive
17	*1228-021* (+)	26.42	26.25	30.22	Positive	27.03	27.35	30.14	Positive
18	*1228-102* (+)	31.50	31.49	26.74	Positive	32.89	34.61	26.33	Positive
19	*1230-044* (+)	32.14	31.84	29.17	Positive	34.78	32.34	29.24	Positive
20	***1229-033 (+)***	ND	ND	29.52	Negative	ND	ND	29.59	Negative
21	*0421-0P1* (-)	ND	ND	25.29	Negative	ND	ND	26.90	Negative
22	*0421-0P2* (-)	ND	ND	26.73	Negative	ND	ND	26.56	Negative
23	*0414-0P3* (-)	ND	ND	28.39	Negative	ND	ND	29.70	Negative
24	*0414-0P4* (-)	ND	ND	27.72	Negative	ND	ND	26.91	Negative
25	*0414-0P5* (-)	ND	ND	27.57	Negative	ND	ND	27.60	Negative
26	*0414-0P6* (-)	ND	ND	28.29	Negative	ND	ND	27.08	Negative

		Commercial Kit				Open RT-qPCR (M-MLV/Taq)			
27	*0414-0P7 (-)*	ND	ND	26.98	Negative	ND	ND	26.87	Negative
28	*0414-0P8 (-)*	ND	ND	27.78	Negative	ND	ND	26.03	Negative
29	*0414-0P9 (-)*	ND	ND	25.34	Negative	ND	ND	26.26	Negative
30	*0414-P10 (-)*	ND	ND	29.45	Negative	ND	ND	28.64	Negative
31	*0414-P11 (-)*	ND	ND	28.95	Negative	ND	ND	28.88	Negative
32	*0414-P12 (-)*	ND	ND	26.98	Negative	ND	ND	27.07	Negative
33	*0414-P13 (-)*	ND	ND	26.54	Negative	ND	ND	26.11	Negative
34	0414-P14 (-)	ND	ND	25.16	Negative	ND	ND	26.56	Negative
35	*0414-P15 (-)*	ND	ND	27.11	Negative	ND	ND	27.90	Negative
36	*0414-P16 (-)*	ND	ND	29.74	Negative	ND	ND	28.50	Negative
37	*0414-P17 (-)*	ND	ND	25.85	Negative	ND	ND	28.14	Negative
38	*0414-P18 (-)*	ND	ND	27.74	Negative	ND	ND	29.20	Negative
39	*0414-P19 (-)*	ND	ND	25.45	Negative	ND	ND	26.87	Negative
40	*0414-P20 (-)*	ND	ND	28.67	Negative	ND	ND	27.45	Negative

Comparative Cq data for the TaqPath One-Step RT-qPCR kit and the probe-based open RT-qPCR reaction mix. Assigned sample number (# Sample) and clinical sample identifier (ID) are displayed. The clinical reports of the samples before they were re-tested by the two kits are also indicated in parentheses. The sample whose report was altered is denoted in bold. **(-):** negative samples, **(+):** positive samples, **ND:** non-detected.

Figure 2: Probe-based Open One-Step RT-qPCR reaction mix (M-MLV RT and Taq DNA pol) provides comparable results to commercial kits in SARS-CoV-2 clinical samples. Scatterplot of the Cq values of positive (blue circles) and negative (red squares) samples obtained by the commercial and open RT-qPCR reaction master mixes using the N1 and N2 primer/probe sets (**A** and

B, respectively). The numbers displayed in each sample match those displayed in Table 3 (# Sample).
If a Cq value was not detected in the sample, it appears in the ND area of the graph depending on
whether this occurred in the commercial kit (green rectangle), the open probe-based kit (gray
rectangle), or both (intersections between the rectangles). For each combination of primers and
probes, the linear trend of the positive samples is shown (blue dotted line) along with the
corresponding value of r^2. **ND:** non-detected
292

Despite the non-specific amplification obtained with the dye-based One-Step RT-qPCR

reaction mix (M-MLV RT/Pfu-Sso7d), 33 clinical nasopharyngeal samples were evaluated

with this mix in order to assess a correlation with the TaqPath™ commercial kit.

Supplemental Table 3 displays the Cq values obtained with each of the primer sets (N1, N2,

and RNAse P). The results of the study show that both reaction mixes (homemade and

commercial) were able to detect the presence of SARS-CoV-2 virus in the positive samples

analyzed. However, the homemade dye-based assay showed non-specific amplification, as

it identified three negative samples as positive and six as indeterminate, indicating insufficient

specificity for clinical analysis. In contrast, the commercial kit accurately reported all negative

samples. These results demonstrate the high sensitivity of the dye-based assay, with all 24

positive samples correctly identified. However, the assay's specificity is insufficient for clinical

analysis as none of the 9 negative samples were correctly identified. Moreover, the dye-based

kit and the commercial kit provided comparable results for the RNAse P control, with mean

Cq values of 28.04 and 28.2, respectively. Despite the inability of the dye-based RT-qPCR

method to accurately report the negative samples, there was a high correlation between the

Cq values of positive nasopharyngeal samples of both kits **(Supplemental Figure 4A and**

B). Therefore, once modified and optimized to increase discrimination between positive and

negative samples, this dye-based test could serve as a valuable resource.

In summary, these findings demonstrate the effectiveness of the homemade, probe-based

One-Step RT-qPCR reaction mix in detecting SARS-CoV-2 RNA in clinical samples and

different viral synthetic RNA dilutions. Additionally, this reaction mix provides Cq values

comparable to those of the TaqPath reaction mix, allowing for efficient classification of positive

and negative samples. These results emphasize the potential for local production of

homemade M-MLV RT and Taq DNA pol, as well as master mixes, for clinical use. This is

particularly crucial for low- and middle-income countries to respond to health crises with

greater autonomy and at lower economic costs.

Discussion

Clinical laboratory testing has played a crucial role in the global response to COVID-19,

enabling rapid diagnosis, early intervention, and accurate disease detection and control [63].

Furthermore, open science communities that emphasize open access, open data, and open

source have been essential in promoting democratic and rapid responses to the epidemic's

global crisis. Given that One-Step RT-qPCR remains the widely accepted gold standard

approach for detecting SARS-CoV-2 [20,21], an open One-Step RT-qPCR method was

developed to identify SARS-CoV-2 RNA in clinical samples. This open RT-qPCR approach

uses recombinant enzymes and a non-proprietary buffer, which can be produced locally to

address the high demand and supply chain bottlenecks that are hindering the COVID-19

health and public policy response [64].

We used a highly processive and thermostable MMLV-RT enzyme [59] for cDNA synthesis,

and two DNA polymerases for DNA amplification to perform both probe-based (Taq DNA pol

[36]) and dye-based assays (Pfu-Sso7d [60]). The molecular assay based on homemade M-

MLV RT and Taq DNA pol produced results comparable to those obtained using commercial

kits **(Table 3 and Figure 2)**. With high specificity (100%) and sensitivity (95%), this

combination of locally produced enzymes successfully discriminated between negative and

positive patients for SARS-CoV-2 infection in nasopharyngeal swab samples. Although one

sample was mislabeled in both the commercial and homemade kits, nearly all samples

(39/40) were correctly labeled. Since the samples were retested simultaneously by both kits,

sample degradation during transport and the impact of freeze-thaw cycles are the most

plausible explanations for this discrepancy. Similar reasons have been suggested to account

for variations or changes in Cq values of clinical samples [36].

On the other hand, although dye-based detection using intercalating agents such as

EvaGreen is a more cost-effective alternative to probe-based assays, the probe-independent

assay developed in this study using M-MLV RT and Pfu-Sso7d was not able to replicate the

results of the commercial kit **(Supplemental Table 3 and Supplemental Figure 4)**. Synthetic

RNA assays targeting the N gene also revealed that the dye-based assay had a higher

detection limit than the probe-based assay **(Figure 1 and Supplemental Figure 3)**, with the

latter achieving a similar detection limit to that reported for commercial kits commonly used

in clinical settings [36].

In addition, when EvaGreen was used as an intercalating agent, melting curves showed non-

specific amplification in NTC and low-concentration RNA samples **(Supplemental Figure 3)**.

This is likely due to the fact that intercalating agents bind to any dsDNA generated during the

reaction, as previously described for dye-based assays using this set of primers [65,66]. As

a result, this assay performed poorly and had limited specificity when compared to a

commercial kit **(Supplemental Table 3)**, despite its high correlation with positive samples

(Supplemental Figure 4). One potential solution to the issue of mislabeling negative samples

using the dye-based approach could be to establish a cut-off cycle at which non-specific

products arise, thus reducing the incidence of false positives, without substantially affecting

the LOD. Strategies such as using an AmpErase Uracil N-Glycosylase (UNG) or Uracil-DNA

Glycosylase (UDG) step prior to PCR to control carry-over contamination have also been

suggested [67,68]. However, compared to probe-based approaches, these solutions require

significantly more technical expertise and time, making them difficult and expensive to

implement in clinical laboratories of LMICs.

Another important reason to prefer the probe-based approach is its ability to amplify multiple

amplicons simultaneously, allowing for multiplex reactions. Although the use of sequence-

specific fluorescently labeled probes can increase diagnostic test costs, probe-based qPCR

procedures provide specificity and precision, resulting in long-term cost savings. The CDC-

recommended Influenza SARS-CoV-2 Multiplex Assay, for instance, is a laboratory test that

can diagnose and distinguish between influenza A, influenza B, and SARS-CoV-2 in upper or

lower respiratory samples [69].

This enables laboratories to conserve critical testing resources, process more tests in a given

time frame, and perform continuous flu monitoring while simultaneously screening for SARS-

CoV-2. Additionally, genotyping of SARS-CoV-2 genome samples has revealed that almost

all of the current COVID-19 diagnostic targets have undergone mutations [70], underscoring

the need for genomic surveillance and rapid variant recognition to comprehend local

epidemiology. Multiplexed reactions provide an excellent opportunity to monitor emerging

SARS-CoV-2 VOC using specific probes for different genes [71-73] or different variants of the

same target [74-76].

To facilitate the local production of the enzymes used in the present study, detailed

purification protocols for each of them have been provided on the open-access platform

protocols.io (**See materials and methods**). This platform was chosen because it improves

collaboration and recordkeeping from which all potential users of the Open One-Step RT-

qPCR can benefit. The purification protocols provided in this platform were designed with the

potential limitations in infrastructure and equipment availability of laboratories in LMIC in mind.

To do this, the use of liquid chromatography instruments was avoided and the use of costly

compounds, such as reducing agents and detergents, was minimized. The non-proprietary

buffer used in the probe-based method was elaborated with cost-cutting in mind, and was

made up of reagents that are typically found in molecular biology and biochemistry

laboratories at most academic institutions (Tris-HCL, KCl, NH_4OAc, $MgSO_4$, DTT, Triton X-

100 and BSA). Additionally, the ReClone collaborative network simplifies the distribution of

the plasmids necessary for the expression of the recombinant proteins utilized in this work,

ensuring and facilitating access to these genetic resources.

The impact of SARS-CoV2 can be lessened globally in low resource settings and commercial

kit shortages by using open solutions to enzyme production and distribution. In this context,

our findings support an Open One-Step RT-qPCR setup compatible with Taqman probes

used in clinical diagnostic laboratories. Furthermore, the results here show sensitivity and

discrimination capacity comparable to commercial kits. This work represents a proof-of-

principle of how open collaborative efforts can be key to respond to emergencies such as that

imposed by the COVID-19 pandemic.

Materials & Methods

<u>Biological Samples</u>

Forty nasopharyngeal swabs were collected from potential COVID-19 patients in the Metropolitan Region of Chile as part of an active surveillance effort and processed in the Molecular Virology Laboratory at the University of Santiago of Chile. RNA was extracted using the E.Z.N.A. Total RNA Kit I (Omega Biotek) according to the manufacturer's instructions. The SARS-CoV-2 virus was detected using the commercial GenomeCoV19 Detection Kit (Applied Biological Materials Inc.) in an Aria Mx Thermocycler (Agilent) with the thermal cycle program suggested by Applied Biological Materials (ABM). Samples with amplifications in both the N and S genes were considered positive according to the manufacturer's instructions. All methods and procedures were performed in accordance with relevant guidelines and regulations approved by the Ethics Committee of the Universidad de Santiago de Chile, and informed consent was obtained from all participants and/or their legal guardians.

On the other hand, 33 nasopharyngeal swabs in Universal Transport Medium (UTM) were collected from symptomatic cases of COVID-19 consultants at the UC-Christus Health Network in Chile. RNA was automatically extracted using the Mag-Bind RNA Extraction Kit (Maccura Biotechnology CO., LTD) according to the manufacturer's instructions. The samples were tested using the RT-qPCR commercial kit LightMix® SARS-CoV-2 RdRp-gene EAV PSR & Ctrl (TIB MOLBIOL) in a LightCycler® 480 real-time PCR system (Roche). The data was analyzed using the 2nd Derivative Maximum Method to obtain the quantification cycle (Cq) value for each sample. The samples were processed in the Clinical Laboratory of Medicine School. The Ethical Review Board of the Faculty of Medicine, Pontificia Universidad Católica de Chile (code: 210105007) approved the use of these biological samples for

diagnostic tests. Informed consent was obtained from all participants and/or their legal

guardians.

<u>Enzyme cloning, expression and purification</u>

The plasmid encoding the codon-optimized Pfu-Sso7d was obtained from Dr. Alexander

Klenov at York University and his full sequence can be found at https://benchling.com/s/seq-

2TcUPjO2uMbDG5ufTQN4. The E602D mutant Taq polymerase plasmid was obtained from

Dr. Robert Tjian and his sequence is available in Addgene (Addgene plasmid # 166944;

http://n2t.net/addgene:166944). The M-MLV RT-encoding plasmid was synthesized as a

gBlock (IDT) with an additional N-terminal region of 8 amino acids containing a peptide leader.

This M-MLV contains point mutations D200N, L603W, T330P, L139P, and E607K shown to

increase thermostability and processivity[59]. The enzymes *Nde*I and *Bam*HI were then used

to clone the synthesized fragment into a pET-19 vector with an N-terminal 10x His-tag. Finally,

the sequence constructs were verified by Sanger sequencing services (Eton Bio) to ensure

their accuracy. The sequence of the plasmid encoding the codon-optimized M-MLV RT can

be found at https://benchling.com/s/seq-6YsA1HcMYoR39E5AqLDT?m=slm-

oAWHvEjeD6BMVH8n9Un5.

Detailed protocols were used to purify all proteins expressed in this work, and a description

of these optimized protocols can be found in the open-access platform protocols.io[60,77,78].

Briefly, the three DNA constructs were independently transformed into *E. coli* T7 expression

strains BL21(DE3) (for M-MLV RT) or C41(DE3) (for Pfu-Sso7d and Taq DNA pol). Single

colonies were first picked into a pre-inoculum of liquid LB media and allowed to grow overnight

at 37 °C with constant agitation at 200-250 rpm. The saturated cultures were then used to

inoculate 1 L of LB media and grew with constant agitation at 160-200 rpm at 37 °C until the

OD_{600} reached 0.8. At this point, protein overexpression was induced by adding isopropyl β-

D-1-thiogalactopyranoside (IPTG) to a final concentration of 0.5 mM and incubated for 16 h

at 160 rpm and 18 °C for Pfu-Sso7d and MMLV, while incubation was only 2 h at 37 °C for

Taq DNA pol[60,77,78].

Cells were harvested by centrifugation and resuspended in a lysis buffer containing lysozyme

at approximately 0.2 mg/mL. The cells were then disrupted by incubating them at room

temperature for 20-30 minutes with constant agitation at 80 rpm to allow for enzymatic lysis.

The resulting lysate was then sonicated to further encourage cell lysis and fragment bacterial

DNA. For the thermostable enzymes Pfu-Sso7d and Taq DNA polymerase, this step was

followed by a 30 min heat shock at 70-75 °C. The crude lysate was then clarified by

centrifugation and the soluble fraction was collected for further purification steps[60,77,78].

Proteins were purified from the clarified lysate by two subsequent purification using affinity

chromatography. First, a Ni-NTA IMAC purification was performed, obtaining a target protein

purity >80%. The pooled fractions from IMAC were then subjected to heparin affinity

chromatography to simultaneously eliminate protein and nucleic acid impurities. The purity of

the eluted protein fractions was evaluated by SDS-PAGE, and the purest fractions were

pooled and quantified using the Bio-Rad Protein Assay (Bio-Rad), with concentrations of the

protein solutions being estimated based on a BSA calibration curve. Finally, the pooled

protein fractions were supplemented with different chemical reagents needed to reach their

storage conditions, as detailed for each protein in the protocols available at

protocols.io[60,77,78].

<u>Assessment of enzymatic functionality</u>

The functionality of DNA polymerase was evaluated by amplifying different DNA fragment

sizes (122, 427, and 1067 base pairs) from a plant organism (*Arabidopsis thaliana*) unrelated

to the SARS-CoV-2 virus. For these assays, 0.3 µg of homebrewed Pfu-Sso7d were

compared to 0.4 U of Phusion High-Fidelity DNA Polymerase (Thermo Scientific), which was

used as a positive control. Both enzymes were run in the presence of 5X Phusion HF Buffer

(Thermo Scientific). A Two-Step RT-PCR reaction was then carried out to evaluate the

reverse transcriptase activity of the homebrewed M-MLV-RT. For this reaction, 3 ng of home-

brewed M-MLV-RT and 0.3 µg of home-brewed Pfu-Sso7d were used for cDNA synthesis

and DNA amplification, respectively. A known sample of plant RNA was used in these assays,

with ImProm-II RT (Promega) serving as a positive control for reverse transcriptase activity.

Commercial reaction buffers ImProm-II 5X (Promega) and 5X Phusion HF Buffer (Thermo

Scientific) were used, and 5 mM dithiothreitol (DTT) and 20 mM β-mercaptoethanol (BME)

were tested as reducing agents.

Once the functionalities of the polymerase and reverse transcriptase enzymes were

confirmed, both were evaluated in a One-Step RT-PCR using a homemade buffer composed

of 150 mM Tris-HCl pH 8.4, 50 mM KCl, 50 mM NH_4OAc, 15 mM $MgSO_4$, 50 mM DTT, 0.5%

Triton X-100, and 0.5 mg/mL BSA. This homemade buffer was optimized by individually

adjusting all components within the following ranges: 100-600 mM Tris-HCl pH 7-8.5, 10-400

mM KCl, 5-250 mM NH_4OAc, 1-20 mM $MgSO_4$, 50-100 mM DTT, 0.1-0.5% Triton X-100, and

0.01-1 mg/mL BSA. In parallel, a One-Step RT-PCR using 0.4 µg of homemade Taq DNA

polymerase instead of Pfu-Sso7d was evaluated using the same conditions described above.

In both cases, 1 and 0.5 µg of plant RNA from a known sample were used as a template.

In vitro transcription of N gene RNA from MERS-CoV, SARS-CoV-1 and SARS-CoV-2

Synthetic viral RNA was used for preliminary RT-PCR evaluation using homebrew M-MLV

RT along with either Pfu-Sso7d or Taq DNA pol. The positive controls for the N genes from

MERS-CoV, SARS-CoV-1 and SARS-CoV-2 were purchased from IDT (Cat # 10006623,

10006624, and 10006625, respectively), from which overhang PCR was performed to

generate RNAP T7 transcriptional units of the full-length N genes, using the following primers:

NT_Fw (5'-CGAAATTAATACGACTCACTATAGGGGCAACGCGATGACGATGGA TAG -3')

and *T7_Nter_Rv* (5'- ACTGATCAAAAAACCCCTCAAGACCCGTTTAGAG

GCCCCAAGGGGGTTATGCTAGTTAGGCCTGAGTTGAGTCAG -3').

The PCR products were purified from agarose gel electrophoresis using a Wizard Sv Gel

Clean-up system (Promega) and further used in an in vitro transcription reaction at 37 °C for

16 h (Hi Scribe, NEB) using 2 μL of each ribonucleotide (100 mM), 2 μL of 10X Reaction

Buffer (NEB), 0.5 μL of RNAsin (Promega), 0.5 μL of Pyrophosphatase (NEB), 2 μL of T7

polymerase Mix (NEB) and 7 μL of the N gene dsDNA linear fragment (40 ng/μL).

Subsequently, a DNAse I treatment was performed to remove the DNA template by adding

70 μL of ultrapure water, 10 μL 10X DNAse I Buffer, and 2 μL of DNAse I (NEB), followed by

incubation of the sample at 37 °C for 15 min. Finally, the RNA product was purified with an

RNeasy kit following the provider's instructions (Qiagen), obtaining 50 μL of the viral N RNA

at a concentration of 1,000 ng/μL.

RT-qPCR analysis using synthetic RNA

Probe-based Open One-Step RT-qPCR (reaction mix and cycling conditions described in

Tables 1 and **2**, respectively) and dye-based Open One-Step RT-qPCR (**Supplementary**

Tables 1 and **2**, respectively) were evaluated on *in vitro*-transcribed N gene RNA samples.

Probe-based RT-qPCR was performed using specific primers for the SARS-CoV-2

nucleocapsid (N) coding gene and the human RNAse P gene (N1, N2 and RNAse P primer

sets, **Table 4**), as well as double-quenched probes (N1, N2 and RNAse P 5' FAM / ZEN™ /

3' Iowa Black™ FQ probes). Dye-based RT-qPCR used only specific primers for the N gene

and the human RNAse P gene, along with EvaGreen DNA-binding agent. (**Table 4**). Both

assays were carried out using the homemade RT-qPCR reaction buffer (150 mM Tris-HCl pH

8.4, 50 mM KCl, 50 mM NH_4OAc, 15 mM $MgSO_4$, 0.5 % Triton X-100 and 0.5 mg/mL BSA)

and 100 mM DTT. Serial dilutions in the range of 1.4 x 10^7 to 1.4 x 10^1 copies of synthetic

RNA were used as templates. RT-qPCR reaction mixes were prepared just before use and

kept on ice until transferred to a StepOnePlus Real-Time PCR System instrument (Applied

Biosystems).

Table 4. Primers used in One-Step qRT-PCR reactions.

Name	Target	Sequence (5'→3')*
2019-nCoV_N1-F	SARS-CoV-2 N gen Forward primer	GACCCCAAAATCAGCGAAAT
2019-nCoV_N1-R	SARS-CoV-2 N gene Reverse primer	TCTGGTTACTGCCAGTTGAATCTG
2019-nCoV_N1-P	SARS-CoV-2 N gene Probe	**FAM**-ACCCCGCAT/**ZEN**/TACGTTTGGTGGACC-**3IABkFQ****
2019-nCoV_N2-F	SARS-CoV-2 N gene Forward primer	TTACAAACATTGGCCGCAAA
2019-nCoV_N2-R	SARS-CoV-2 N gene Reverse primer	GCGCGACATTCCGAAGAA
2019-nCoV_N2-P	SARS-CoV-2 N gene Probe	**FAM**-ACAATTTGC/**ZEN**/CCCCAGCGCTTCAG-**3IABkF****
RP-F	Human RNAse P gene Forward primer	AGATTTGGACCTGCGAGCG
RP-R	Human RNAse P gene Reverse primer	GAGCGGCTGTCTCCACAAGT
RP-P	Human RNAse P gene Probe	**FAM**-TTCTGACCT/**ZEN**/GAAGGCTCTGCGCG-**3IABkFQ****

* Primers and probes sequences used correspond to those described in the CDC list of Research Use Only RT-
qPCR Primers and Probes[22]. Sequences may have changed according to the evolution of SARS-CoV-2.
** Probes are 5′end-labeled with the reporter molecule 6-carboxyfluorescein (**FAM**) and 3′end-labeled with a
double quencher, **ZEN**™ Internal Quencher and Iowa Black® FQ (**3IABkFQ**).

<u>RT-qPCR analysis using clinical samples</u>

The Open One-Step RT-qPCR kits were validated using clinical samples that were previously

labeled as positive or negative for SARS-CoV-2 in clinical or molecular virology laboratories.

A total of 40 clinical samples (20 positives and 20 negatives) were reevaluated using both a

commercial kit (TaqPath™ 1-Step RT-qPCR Master Mix) and our probe-based RT-qPCR

reaction mix. The commercial kit was used according to the recommended conditions

indicated by the supplier, while the probe-based RT-qPCR reaction mix was used following

the previously described conditions in **Tables 1** and **2**. Both kits used primers and probes for

the N1 and N2 targets of the SARS-CoV-2, as well as the human RNAse P gene target as an

endogenous internal control (**Table 4**). Additionally, 33 samples were retested using the same

commercial kit (TaqPath™ 1-Step RT-qPCR Master Mix) and our dye-based RT-qPCR

reaction mix (conditions described in **Supplementary Tables 1** and **2**).

The One-Step RT-qPCR reaction mixes were prepared just before use and kept on ice until

they were transferred to a StepOnePlus Real-Time PCR System instrument (Applied

Biosystems). Cutoff points for Cq values required to determine whether a result is COVID-19

positive or negative were specified by the CDC. To report a positive result, both viral targets

N1 and N2 must have a Cq value < 40. To report a negative result, both viral targets must

have a Cq value ≥ 40. If one of the viral targets has a Cq value < 40 and the other has a Cq

value ≥ 40, the result is reported as indeterminate. In addition, the samples were considered

valid only if the Cq value of the RNase P target was ≤ 35.

The specificity and sensitivity of the assays were considered in each analysis. Specificity was

calculated as the number of true negatives over the sum of true negatives and false positives,

whereas sensitivity was calculated as the number of true positives over the sum of true

positives and false negatives.

To determine the correlation between the Cq values of positive samples from Open One-Step

RT-qPCR and commercial kits, a Pearson correlation analysis was performed using the

GraphPad Prism 8 software. The r^2 was calculated for each of these cases and significance

was evaluated with an alpha = 0.05.

Acknowledgments

Thanks to Gina Dailey, Thomas Graham, Robert Tjian and Xavier Darzacq (University of

California Berkeley) for sharing the Taq DNA pol plasmid. We also acknowledge the gracious

help of Amparo Nuñez during the protein purification processes in the final stages of this work.

We thank members of the gLAMP consortium, ReClone forum (https://reclone.org/), Open

Bioeconomy Lab (https://openbioeconomy.org/) and the JOGL OpenCOVID community

(https://app.jogl.io/program/opencovid19) for the advice and for sharing relevant information

for the establishment of diagnostic reactions for SARS-CoV-2. Finally, we also thank Laura

Delgado and Alejandro Fonseca for helping with the manuscript.

576
577 **Author Contributions**

578 AC, CIH, RAG, CARS and FF designed research; MR, JR, PBS, JA, AA, AS, AJB, YV, MCS,

579 PG and MF performed research; AC, CIH, MR, GA, CARS and FF analyzed data; AC, GA,

580 MR, FC, RAG, CARS and FF wrote the manuscript. All authors reviewed the manuscript.

581
Funding

This work was supported by the National Agency for Research and Development (ANID)

through the ANID Millennium Science Initiative Program (ICN17_022) to RAG, CARS and FF.

Fondo de Desarrollo de Areas Prioritarias (Center for Genome Regulation;

ANID/FONDAP/15090007), to RAG and FF. Fondo de Desarrollo Científico y Tecnológico

(FONDECYT 1201684 awarded to CARS, FONDECYT Regular 1211218 to FF, and

FONDECYT 3190731 to MR), and an International Cooperation Program with Consejo

Nacional de Ciencia, Tecnología e Innovación Tecnológica (ANID-CONCYTEC covbio0012

awarded to FF and CARS). This work was also supported by the National Institutes of Health

NIAID training grant (Training Program in Immunology; T32-AI07405) awarded to AJB. PBS

and JR were supported by ANID Doctoral Scholarships (21191979 and 21191684,

respectively). The funders had no role in study design, data collection and analysis, decision

to publish, or preparation of the manuscript.

595
596 **Competing interests**

597 The authors have declared that no competing interests exist.
598

Data Availability

600 All data generated or analyzed during this study are included in this published article, its

601 Supplementary Information files and the Zenodo open data repository

602 [https://doi.org/10.5281/zenodo.7551378].

603 Correspondence and requests for any materials or additional information should be

604 addressed to the corresponding authors (RAG, CARS or FF) on reasonable request.

References

1. Mohamadian, M., et al., *COVID-19: Virology, biology and novel laboratory diagnosis.* J Gene Med, 2021. **23**(2): p. e3303.

2. (WHO), W.H.O. *Weekly epidemiological update on COVID-19 - 1 June 2022.* 2022 [cited 2022 June, 2022]; Available from: https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---1-june-2022.

3. (WHO), W.H.O. *14.9 million excess deaths associated with the COVID-19 pandemic in 2020 and 2021.* 2022 [cited 2022 June, 2022]; Available from: https://www.who.int/news/item/05-05-2022-14.9-million-excess-deaths-were-associated-with-the-covid-19-pandemic-in-2020-and-2021.

4. Beitler, J.R., et al., *Ventilator Sharing during an Acute Shortage Caused by the COVID-19 Pandemic.* Am J Respir Crit Care Med, 2020. **202**(4): p. 600-604.

5. Boškoski, I., et al., *COVID-19 pandemic and personal protective equipment shortage: protective efficacy comparing masks and scientific methods for respirator reuse.* Gastrointestinal endoscopy, 2020. **92**(3): p. 519-523.

6. Park, C.K., K. Roth, S., et al., *Global Shortage of Personal Protective Equipment amid COVID-19: Supply Chains, Bottlenecks, and Policy Implications.* ADB Briefs, 2020.

7. Wu, H.-l., et al., *Facemask shortage and the novel coronavirus disease (COVID-19) outbreak: Reflections on public health measures.* EClinicalMedicine, 2020. **21**: p. 100329.

8. Rahmandad, H., T.Y. Lim, and J. Sterman, *Estimating COVID-19 under-reporting across 86 nations: implications for projections and control.* 2020, medRxiv.

9. Wu, S.L., et al., *Substantial underestimation of SARS-CoV-2 infection in the United States.* Nature Communications, 2020. **11**(1): p. 4507.

10. Abbasi-Oshaghi, E., et al., *Diagnosis and treatment of coronavirus disease 2019 (COVID-19): Laboratory, PCR, and chest CT imaging findings.* Int J Surg, 2020. **79**: p. 143-153.

11. Ejazi, S.A., S. Ghosh, and N. Ali, *Antibody detection assays for COVID-19 diagnosis: an early overview.* Immunol Cell Biol, 2021. **99**(1): p. 21-33.

12. Seyed Hosseini, E., et al., *The novel coronavirus Disease-2019 (COVID-19): Mechanism of action, detection and recent therapeutic strategies.* Virology, 2020. **551**: p. 1-9.

13. Sharma, A., I. Ahmad Farouk, and S.K. Lal, *COVID-19: A Review on the Novel Coronavirus Disease Evolution, Transmission, Detection, Control and Prevention.* Viruses, 2021. **13**(2): p. 202.

14. Wu, J., et al., *Chest CT Findings in Patients With Coronavirus Disease 2019 and Its Relationship With Clinical Features.* Investigative Radiology, 2020. **55**(5): p. 257-261.

15. Jin, Y.H., et al., *A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version).* Mil Med Res, 2020. **7**(1): p. 4.

16. Loeffelholz, M.J. and Y.-W. Tang, *Laboratory diagnosis of emerging human coronavirus infections – the state of the art.* Emerging Microbes & Infections, 2020. **9**(1): p. 747-756.

17. Tahamtan, A. and A. Ardebili, *Real-time RT-PCR in COVID-19 detection: issues affecting the results.* Expert Review of Molecular Diagnostics, 2020. **20**(5): p. 453-454.

18. Vashist, S.K., *In Vitro Diagnostic Assays for COVID-19: Recent Advances and Emerging Trends.* Diagnostics, 2020. **10**(4): p. 202.

19. Chan, J.F., et al., *Improved Molecular Diagnosis of COVID-19 by the Novel, Highly Sensitive and Specific COVID-19-RdRp/Hel Real-Time Reverse Transcription-PCR Assay Validated In Vitro and with Clinical Specimens.* J Clin Microbiol, 2020. **58**(5).

20. CDC. *CDC 2019-Novel Coronavirus (2019-nCoV) Real-Time RT-PCR Diagnostic Panel.* 2020 [cited 2021; Available from: https://www.fda.gov/media/134922/download.

21. Lu, X., et al., *US CDC Real-Time Reverse Transcription PCR Panel for Detection of Severe Acute Respiratory Syndrome Coronavirus 2. .* Emerging Infectious Diseases, 2020. **26**(8): p. 1654-1665.

22. (WHO), W.H.O. *Laboratory testing for 2019 novel coronavirus (2019-nCoV) in suspected*
human cases. 2020 [cited 2022 June, 2022]; Available from:
https://www.who.int/publications/i/item/10665-331501.
23. (WHO), W.H.O. *Tracking SARS-CoV-2 variants.* 2022 [cited 2022 June, 2022]; Available
from: https://www.who.int/activities/tracking-SARS-CoV-2-variants/tracking-SARS-CoV-2-
variants.
24. CDC. *Research Use Only 2019-Novel Coronavirus (2019-nCoV) Real-time RT-PCR Primers*
and Probes. 2020 [cited 2021 March 2021]; Available from:
https://www.cdc.gov/coronavirus/2019-ncov/lab/rt-pcr-panel-primer-probes.html.
25. CDC. *Interim Guidelines for Collecting and Handling of Clinical Specimens for COVID-19*
Testing. 2022 [cited 2022 June, 2022]; Available from:
https://www.cdc.gov/coronavirus/2019-ncov/lab/guidelines-clinical-specimens.html.
26. Chu, A.W., et al., *Evaluation of simple nucleic acid extraction methods for the detection of*
SARS-CoV-2 in nasopharyngeal and saliva specimens during global shortage of extraction
kits. J Clin Virol, 2020. **129**: p. 104519.
27. Fomsgaard, A.S. and M.W. Rosenstierne, *An alternative workflow for molecular detection of*
SARS-CoV-2 – escape from the NA extraction kit-shortage, Copenhagen, Denmark, March
2020. Eurosurveillance, 2020. **25**(14): p. 2000398.
28. H., P., et al., *Nasal Swab Sampling for SARS-CoV-2: a Convenient Alternative in Times of*
Nasopharyngeal Swab Shortage. Journal of Clinical Microbiology, 2020. **58**(6): p. e00721-20.
29. Moreno-Contreras, J., et al., *Saliva Sampling and Its Direct Lysis, an Excellent Option To*
Increase the Number of SARS-CoV-2 Diagnostic Tests in Settings with Supply Shortages. J
Clin Microbiol, 2020. **58**(10).
30. Ben-Ami, R., et al., *Large-scale implementation of pooled RNA extraction and RT-PCR for*
SARS-CoV-2 detection. Clinical Microbiology and Infection, 2020. **26**(9): p. 1248-1253.
31. Eberhardt, J.N., N.P. Breuckmann, and C.S. Eberhardt, *Multi-Stage Group Testing Improves*
Efficiency of Large-Scale COVID-19 Screening. J Clin Virol, 2020. **128**: p. 104382.
32. Farfan, M.J., et al., *Optimizing RT-PCR detection of SARS-CoV-2 for developing countries*
using pool testing. Rev Chilena Infectol, 2020. **37**(3): p. 276-280.
33. Garg, J., et al., *Evaluation of sample pooling for diagnosis of COVID-19 by real time-PCR: A*
resource-saving combat strategy. J Med Virol, 2021. **93**(3): p. 1526-1531.
34. Yelin, I., et al., *Evaluation of COVID-19 RT-qPCR Test in Multi sample Pools.* Clinical
Infectious Diseases, 2020. **71**(16): p. 2073-2078.
35. Esbin, M.N., et al., *Overcoming the bottleneck to widespread testing: a rapid review of*
nucleic acid testing approaches for COVID-19 detection. RNA, 2020. **26**(7): p. 771-783.
36. Graham, T.G.W., et al., *Open-source RNA extraction and RT-qPCR methods for SARS-CoV-*
2 detection. PLOS ONE, 2021. **16**(2): p. e0246647.
37. Ulloa, S., et al., *A simple method for SARS-CoV-2 detection by rRT-PCR without the use of a*
commercial RNA extraction kit. J Virol Methods, 2020. **285**: p. 113960.
38. Wozniak, A., et al., *A simple RNA preparation method for SARS-CoV-2 detection by RT-*
qPCR. Scientific Reports, 2020. **10**(1): p. 16608.
39. Alcoba-Florez, J., et al., *Fast SARS-CoV-2 detection by RT-qPCR in preheated*
nasopharyngeal swab samples. International Journal of Infectious Diseases, 2020. **97**: p. 66-
68.
40. Barza, R., et al., *Use of a simplified sample processing step without RNA extraction for direct*
SARS-CoV-2 RT-PCR detection. J Clin Virol, 2020. **132**: p. 104587.
41. Genoud, V., et al., *Extraction-free protocol combining proteinase K and heat inactivation for*
detection of SARS-CoV-2 by RT-qPCR. PLOS ONE, 2021. **16**(2): p. e0247792.
42. Ñique, A.M., et al., *A faster and less costly alternative for RNA extraction of SARS-CoV-2*
using proteinase k treatment followed by thermal shock. PLOS ONE, 2021. **16**(3): p.
e0248885.
43. Yamazaki, W., et al., *Development of a point-of-care test to detect SARS-CoV-2 from saliva*
which combines a simple RNA extraction method with colorimetric reverse transcription loop-

731		*mediated isothermal amplification detection.* Journal of Clinical Virology, 2021. **136**: p.
732		104760.
733	44.	Malekshahi, A., et al., *Diagnostic power of one-step and two-step RT-qPCR methods to*
734		*SARS-CoV-2 detection.* BMC Infectious Diseases, 2022. **22**(1): p. 505.
735	45.	Tietze, F., et al., *Crisis-Critical Intellectual Property: Findings From the COVID-19 Pandemic.*
736		IEEE Transactions on Engineering Management, 2022. **69**(5): p. 2039-2056.
737	46.	Oldekop, J.A., et al., *COVID-19 and the case for global development.* World Development,
738		2020. **134**: p. 105044.
739	47.	Shamasunder, S., et al., *COVID-19 reveals weak health systems by design: Why we must*
740		*re-make global health in this historic moment.* Global Public Health, 2020. **15**(7): p. 1083-
741		1089.
742	48.	Belhouideg, S., *Impact of 3D printed medical equipment on the management of the Covid19*
743		*pandemic.* The International Journal of Health Planning and Management, 2020. **35**(5): p.
744		1014-1022.
745	49.	Frazer, J.S., A. Shard, and J. Herdman, *Involvement of the open-source community in*
746		*combating the worldwide COVID-19 pandemic: a review.* Journal of Medical Engineering &
747		Technology, 2020. **44**(4): p. 169-176.
748	50.	Maia Chagas, A., et al., *Leveraging open hardware to alleviate the burden of COVID-19 on*
749		*global health systems.* PLOS Biology, 2020. **18**(4): p. e3000730.
750	51.	Pearce, J.M., *A review of open source ventilators for COVID-19 and future pandemics.*
751		F1000Research, 2020. **9**: p. 218-218.
752	52.	Bhadra, S., et al., *A One-enzyme RT-qPCR Assay for SARS-CoV-2, and Procedures for*
753		*Reagent Production.* Bio-protocol, 2021. **11**(2): p. e3898.
754	53.	Kellner, M.J., et al., *A Rapid, Highly Sensitive and Open-Access SARS-CoV-2 Detection*
755		*Assay for Laboratory and Home Testing.* Frontiers in Molecular Biosciences, 2022. **9**.
756	54.	Mascuch, S.J., et al., *A blueprint for academic laboratories to produce SARS-CoV-2*
757		*quantitative RT-PCR test kits.* Journal of Biological Chemistry, 2020. **295**(46): p. 15438-
758		15453.
759	55.	Matute, T., et al., *Homebrew reagents for low-cost RT-LAMP.* Journal of biomolecular
760		techniques : JBT, 2021. **32**(3): p. 114-120.
761	56.	Ellefson, J.W., et al., *Synthetic evolutionary origin of a proofreading reverse transcriptase.*
762		Science, 2016. **352**(6293): p. 1590-3.
763	57.	Bhadra, S., et al., *One-Enzyme Reverse Transcription qPCR Using Taq DNA Polymerase.*
764		Biochemistry, 2020. **59**(49): p. 4638-4645.
765	58.	Kahl, L., et al., *Opening options for material transfer.* Nature Biotechnology, 2018. **36**(10): p.
766		923-927.
767	59.	Baranauskas, A., et al., *Generation and characterization of new highly thermostable and*
768		*processive M-MuLV reverse transcriptase variants.* Protein Eng Des Sel, 2012. **25**(10): p.
769		657-68.
770	60.	Rivera, M.R., et al. *Recombinant protein expression and purification of codon-optimized Pfu-*
771		*Sso7d.* 2020; Available from: https://protocols.io/view/recombinant-protein-expression-and-
772		purification-of-bhcrj2v6
773	61.	Stevens, R., L. Stevens, and N.C. Price, *The stabilities of various thiol compounds used in*
774		*protein purifications.* Biochemical Education, 1983. **11**(2): p. 70.
775	62.	Wang, X., et al., *Limits of Detection of 6 Approved RT–PCR Kits for the Novel SARS-*
776		*Coronavirus-2 (SARS-CoV-2).* Clinical Chemistry, 2020. **66**(7): p. 977-979.
777	63.	Rasool, G., et al., *COVID-19: Clinical laboratory diagnosis and monitoring of novel*
778		*coronavirus infected patients using molecular, serological and biochemical markers: A*
779		*review.* Int J Immunopathol Pharmacol, 2022. **36**: p. 3946320221115316.
780	64.	Nkengasong, J., *Let Africa into the market for COVID-19 diagnostics.* Nature, 2020.
781		**580**(7805): p. 565.
782	65.	Fuchs Wightman, F., et al., *A DNA intercalating dye-based RT-qPCR alternative to diagnose*
783		*SARS-CoV-2.* RNA Biol, 2021. **18**(12): p. 2218-2225.

66. Tao, Y., et al., *Comparison of analytical sensitivity and efficiency for SARS-CoV-2 primer
sets by TaqMan-based and SYBR Green-based RT-qPCR.* Applied Microbiology and
Biotechnology, 2022. **106**(5): p. 2207-2218.
67. Longo, M.C., M.S. Berninger, and J.L. Hartley, *Use of uracil DNA glycosylase to control
carry-over contamination in polymerase chain reactions.* Gene, 1990. **93**(1): p. 125-8.
68. Wong, W., et al., *Probe-based Real-time PCR Approaches for Quantitative Measurement of
microRNAs.* J Vis Exp, 2015(98).
69. CDC. *CDC's Influenza SARS-CoV-2 Multiplex Assay.* 2022; Available from:
https://www.cdc.gov/coronavirus/2019-ncov/lab/multiplex.html.
70. Wang, R., et al., *Mutations on COVID-19 diagnostic targets.* Genomics, 2020. **112**(6): p.
5204-5213.
71. Sun, Q., et al., *Saliva as a testing specimen with or without pooling for SARS-CoV-2
detection by multiplex RT-PCR test.* PLOS ONE, 2021. **16**(2): p. e0243183.
72. Reijns, M.A.M., et al., *A sensitive and affordable multiplex RT-qPCR assay for SARS-CoV-2
detection.* PLOS Biology, 2020. **18**(12): p. e3001030.
73. Kudo, E., et al., *Detection of SARS-CoV-2 RNA by multiplex RT-qPCR.* PLOS Biology, 2020.
18(10): p. e3000867.
74. Fu, J.Y.L., et al., *SARS-CoV-2 multiplex RT-PCR to detect variants of concern (VOCs) in
Malaysia, between January to May 2021.* J Virol Methods, 2022. **301**: p. 114462.
75. Vogels, C.B.F., et al., *Multiplex qPCR discriminates variants of concern to enhance global
surveillance of SARS-CoV-2.* PLOS Biology, 2021. **19**(5): p. e3001236.
76. Wang, H., et al., *Multiplex SARS-CoV-2 Genotyping Reverse Transcriptase PCR for
Population-Level Variant Screening and Epidemiologic Surveillance.* Journal of Clinical
Microbiology, 2021. **59**(8): p. e00859-21.
77. Rivera, M.R., et al. *Recombinant expression and purification of codon-optimized M-MLV and
Mashup.* 2021 [cited 2021; Available from:
https://dx.doi.org/10.17504/protocols.io.bsernbd6.
78. Rivera, M.R., et al. *Recombinant protein expression and purification of Taq DNA
polymerase.* 2021; Available from: dx.doi.org/10.17504/protocols.io.bya3psgn.
813